Cellares is a pioneering life sciences technology company and an Integrated Development and Manufacturing Organization (IDMO) dedicated to accelerating access to life-saving cell therapies. Cellares focuses on solving the challenges of manual, disconnected, and resource-intensive cell therapy manufacturing processes. Their flagship technology, the Cell Shuttle™, is a fully automated, high-throughput, and closed-platform solution designed to enable scalable, cost-effective, and reliable production of cell therapies from clinical to industrial scale. Cellares aims to make these advanced treatments more accessible to patients worldwide by industrializing manufacturing and offering end-to-end solutions.
Serves as the primary center for corporate leadership, research and development, engineering, and initial manufacturing operations for the Cell Shuttle platform.
State-of-the-art R&D laboratories, GMP-compliant cleanroom facilities for cell therapy process development and manufacturing, advanced automation and robotics integration areas, and collaborative workspaces designed to foster innovation.
A dynamic, mission-driven, and innovative environment characteristic of a rapidly growing biotech company. The culture emphasizes collaboration, scientific excellence, agility, and a patient-centric approach to problem-solving in order to advance cell therapy manufacturing.
The South San Francisco headquarters is pivotal to Cellares's strategy, housing core innovation teams and advanced infrastructure essential for developing, refining, and scaling its groundbreaking Cell Shuttle technology and IDMO services.
Cellares supports cell therapy development and manufacturing globally, with key operational hubs in North America (South San Francisco, CA, and Bridgewater, NJ, USA) and Europe (Stevenage, UK). Their automated Cell Shuttle platform and IDMO services are designed for worldwide deployment, enabling standardized, high-quality manufacturing for clients across different regions. Cellares actively engages with international partners in the pharmaceutical and biotechnology sectors to advance cell therapies worldwide.
1 DNA Way
South San Francisco
CA
USA
Address: 95 BioNJ Way, Bridgewater, NJ 08807, USA
To serve the East Coast biotech hub and provide large-scale, automated cell therapy manufacturing capabilities, supporting the growing demand from pharmaceutical and biotech partners in North America.
Address: Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, UK (Located within the Cell and Gene Therapy Catapult campus)
To provide cell therapy manufacturing solutions and support to European clients, establishing a key operational hub in the UK's prominent cell and gene therapy cluster and facilitating global reach.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cellares' leadership includes:
Cellares has been backed by several prominent investors over the years, including:
Cellares has significantly strengthened its executive team over the past 12-18 months with several key strategic hires in operations, commercial, people, and business leadership to support its rapid growth, global expansion, and scaling of its IDMO Smart Factories.
Discover the tools Cellares uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cellares likely utilizes standard corporate email formats. Common patterns for companies of its type include [first_initial][last] or [first].[last] @companydomain.com.
[first_initial][last]@cellares.com (e.g., jdoe@cellares.com) or [first].[last]@cellares.com (e.g., jane.doe@cellares.com)
Format
fgerlinghaus@cellares.com
Example
80%
Success rate
Cellares / Business Wire • March 12, 2024
Cellares announced the appointment of Scott Ripley as Chief Operating Officer. Ripley will oversee Cellares' operations, manufacturing, supply chain, and quality functions as the company scales its commercial-scale IDMO Smart Factories....more
Cellares / Business Wire • January 9, 2024
Cellares announced the appointment of Dr. Stephen M. Chang as Chief Business Officer. Dr. Chang brings extensive experience in biopharma business development and will lead Cellares' strategic partnerships and corporate development efforts....more
Cellares / Business Wire • November 14, 2023
Cellares announced its expansion into Europe with the acquisition of a state-of-the-art GMP cell therapy manufacturing facility in Stevenage, UK, from the Cell and Gene Therapy Catapult. This facility will serve as Cellares' European Center of Excellence....more
Cellares / Business Wire • July 11, 2023
Cellares announced the close of a $255 million Series C financing round. The funding will be used to launch its first commercial-scale IDMO Smart Factory, expand its technology differentiation, and meet growing global demand for its automated cell therapy manufacturing solutions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cellares, are just a search away.